The limited effect of SGLT2 inhibitors on atherothrombotic disease (11% reduction in MACE in a recent meta-analysis77), and the strong effects on HF and kidney outcomes with early divergence of group outcomes (benefits seen after 3 months), strongly point to a hemodynamic effect that relates to sodium balance as postulated here. The gene discussed is SLC5A2; the disease is hydrops fetalis.